Sepsis associated with immunosuppressive medications: An evidence-based review

Critical Care Medicine

Volumn 32, Issue 11 SUPPL., 2004, Pages

  Gea Banacloche, Juan C ^a   Opal, Steven M ^b   Jorgensen, James ^c   Carcillo, Joseph A ^d   Sepkowitz, Kent A ^e   Cordonnier, Catherine ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN; ANTIINFECTIVE AGENT; AZATHIOPRINE; BASILIXIMAB; BETA LACTAM; CARBAPENEM; CASPOFUNGIN; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; ETANERCEPT; FLUCONAZOLE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LINEZOLID; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; RAPAMYCIN; TACROLIMUS; UNINDEXED DRUG; VANCOMYCIN;

ASPERGILLUS; BACTERIAL INFECTION; CANDIDA; COMBINATION CHEMOTHERAPY; CONSENSUS DEVELOPMENT; CRYPTOCOCCUS; CYTOMEGALOVIRUS; DISEASE SEVERITY; DRUG INDICATION; EVIDENCE BASED MEDICINE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HERPES VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; INTENSIVE CARE; LEGIONELLA; LISTERIA; MOULD; MUCOSA INFLAMMATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; NEUTROPENIA; NOCARDIA; PNEUMOCYSTIS; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; STRONGYLOIDES; SURVIVAL RATE; SYSTEMATIC REVIEW; VIRUS INFECTION;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CONSENSUS DEVELOPMENT CONFERENCES; EVIDENCE-BASED MEDICINE; HEPATITIS, VIRAL, HUMAN; HUMANS; IMMUNE TOLERANCE; IMMUNOCOMPROMISED HOST; IMMUNOPHILINS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; PNEUMONIA; PRACTICE GUIDELINES; SEPSIS; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8444225006     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000143020.27340.FF     Document Type: Review

References (146)

1. Allison AC: Immunosuppressive drugs: The first 50 years and a glance forward. Immunopharmacology 2000;1 47:63-83
2. Husain S, Singh N: The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002; 35:53-61
3. Stuck AE, Minder CE, Frey FJ: Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11:954-963
4. Sepkowitz KA, Brown AE, Armstrong D: Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: More patients, same risk. Arch Intern Med 1995; 155:1125-1128
5. Yale SH, Limper AH: Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: Associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71:5-13
6. Wallace RJ Jr, Brown BA, Onyi GO: Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: Importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166: 405-412
7. Clark TM, Burman WJ, Cohn DL, et al: Septic shock from Mycobacterium tuberculosis after therapy for Pneumocystis carinii. Arch Intern Med 1998; 158:1033-1035
8. Pera A, Byun A, Gribar S, et al: Dexamethasone therapy and Candida sepsis in neonates less than 1250 grams. J Perinatol 2002; 22:204-208
9. Nenoff P, Horn LC, Mierzwa M, et al: Per-acute disseminated fatal Aspergillus fumigatus sepsis as a complication of corticoid-treated systemic lupus erythematosus. Mycoses 1995; 38:467-471
10. Lauerma AI, Jeskanen L, Rantanen T, et al: Cryptococcosis during systemic glucocorticosteroid treatment. Dermatology 1999; 199:180-182
11. Abernathy-Carver KJ, Fan LL, Boguniewicz M, et al: Legionella and Pneumocystis pneumonias in asthmatic children on high doses of systemic steroids. Pediatr Pulmonol 1994; 18:135-138
12. Hui CH, Au VW, Rowland K, et al: Pulmonary nocardiosis re-visited: Experience of 35 patients at diagnosis. Respir Med 2003; 97:709-717
13. Scowden EB, Schaffner W, Stone WJ: Overwhelming strongyloidiasis: An unappreciated opportunistic infection. Medicine (Baltimore) 1978; 57:527-544
14. Wiest PM, Flanigan T, Salata RA, et al: Serious infectious complications of corticosteroid therapy for COPD. Chest 1989; 95: 1180-1184
15. Sayer HG, Longton G, Bowden R, et al: Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994; 84:1328-1332
16. Stoll BJ, Temprosa M, Tyson JE, et al: Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics 1999; 104:e63
17. Genestier L, Paillot R, Fournel S, et al: Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102:322-328
18. LeMense GP, Sahn SA: Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 1994; 150:258-260
19. Boerbooms AM, Kerstens PJ, van Loenhout JW, et al: Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24:411-421
20. Matsuda S, Koyasu S: Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47:119-125
21. Mele TS, Halloran PF: The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000; 47:215-245
22. Paya CV, Fung JJ, Nalesnik MA, et al: Epstein-Barr virus-induced posttransplant lymphoproliferative disorders: ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517-1525
23. Kuypers DR, Evenepoel P, Maes BD, et al: Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. Transplant Proc 2002; 34:1164-1170
24. Kremer JM: Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001; 134: 695-706
25. Keane J, Gershon S, Wise RP, et al: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-1104
26. Kroesen S, Widmer AF, Tyndall A, et al: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003; 42: 617-621
27. Slifman NR, Gershon SK, Lee JH, et al: Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48:319-324
28. Gaston RS, Deierhoi MH, Patterson T, et al: OKT3 first-dose reaction: Association with T cell subsets and cytokine release. Kidney Int 1991; 39:141-148
29. Queen C, Schneider WP, Selick HE, et al: A humanized antibody that binds to the interleukin 2 receptor. Proc Nat Acad Sci U S A 1989; 86:10029-10033
30. Adu D, Cockwell P, Ives NJ, et al: Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials. BMJ 2003; 326:789
31. Cook CH, Zhang Y, McGuinness BJ, et al: Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J Infect Dis 2002; 185:1395-1400
32. Munford RS, Pugin J: Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001; 163:316-321
33. Song GY, Chung CS, Chaudry IH, et al: What is the role of interleukin 10 in polymicrobial sepsis: Anti-inflammatory agent or immunosuppressant? Surgery 1999; 126: 378-383
34. Nomura F, Akashi S, Sakao Y, et al: Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol 2000; 164:3476-3479
35. Varma TK, Toliver-Kinsky TE, Lin CY, et al: Cellular mechanisms that cause suppressed gamma interferon secretion in endotoxin-tolerant mice. Infect Immun 2001; 69: 5249-5263
36. Reddy RC, Chen GH, Tekchandani PK, et al: Sepsis-induced immunosuppression: From bad to worse. Immunol Res 2001; 24: 273-287
37. Ayala A, Song GY, Chung CS, et al: Immune depression in polymicrobial sepsis: The role of necrotic (injured) tissue and endotoxin. Crit Care Med 2000; 28:2949-2955
38. Oberholzer A, Oberholzer C, Moldawer LL: Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002; 30(1 Suppl):S58-S63
39. Weighardt H, Heidecke CD, Emmanuilidis K, et al: Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production. Surgery 2000; 127: 309-315
40. Ayala A, O'Neill PJ, Uebele SA, et al: Mechanism of splenic immunosuppression during sepsis: Key role of Kupffer cell mediators. J Trauma 1997; 42:882-888
41. Hotchkiss RS, Tinsley KW, Swanson PE, et al: Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001; 166:6952-6963
42. Chen GH, Reddy RC, Newstead MW, et al: Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense. J Immunol 2000; 165: 6496-6503
43. Stefanov C, Doikov I, Dimov R, et al: Clinical and bacteriological results from the administration of Cefepime (Maxipime) in patients with severe sepsis. Med Sci Monit 2002; 8:PI97-PI102
44. Allegranzi B, Luzzati R, Luzzani A, et al: Impact of antibiotic changes in empirical therapy on antimicrobial resistance in intensive care unit-acquired infections. J Hosp Infect 2002; 52:136-140
45. Kollef MH, Sherman G, Ward S, et al: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474
46. Ibrahim EH, Sherman G, Ward S, et al: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155
47. Kolleff MH: Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: A necessity, not an issue for debate. Intensive Care Med 2003; 29:147-149
48. Leibovici L, Drucker M, Konigsberger H, et al: Septic shock in bacteremic patients: Risk factors, features and prognosis. Scand J Infect Dis 1997; 29:71-75
49. Valles J, Rello J, Ochagavia A, et al: Community-acquired bloodstream infection in critically ill adult patients: Impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123:1615-1624
50. Critchley IA, Jones ME, Heinze PD, et al: In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002; 8:214-221
51. Martinez-Martinez L, Pascual A, Suarez AI, et al: In-vitro activity of levofloxacin, ofloxacin and D-ofloxacin against coryneform bacteria and Listeria monocytogenes. J Antimicrob Chemother 1999; 43(Suppl C): 27-32
52. Jones RN, Sader HS, Beach ML: Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 2003; 22:551-556
53. Singh N, Gayowski T, Wagener MM, et al: Clinical spectrum of invasive cryptococcosis in liver transplant recipients receiving tacrolimus. Clin Transplant 1997; 11:66-70
54. Lozano F, Gomez-Mateos J, Irles JA, et al: Fulminant septic shock in AIDS patients caused by disseminated cryptococcosis. Eur J Clin Microbiol Infect Dis 1999; 18: 151-152
55. Koduri PR, Chundi V, DeMarais P, et al: Reactive hemophagocytic syndrome: A new presentation of disseminated histoplasmosis in patients with AIDS. Clin Infect Dis 1995; 21:1463-1465
56. Lopez AM, Williams PL, Ampel NM: Acute pulmonary coccidioidomycosis mimicking bacterial pneumonia and septic shock: A report of two cases. Am J Med 1993; 95: 236-239
57. Simarro E, Marin F, Morales A, et al: Fungemia due to Scedosporium prolificans: A description of two cases with fatal outcome. Clin Microbiol Infect 2001; 7:645-647
58. Raj R, Frost AE: Scedosporium apiospermum fungemia in a lung transplant recipient. Chest 2002; 121:1714-1716
59. Ochiai N, Shimazaki C, Uchida R, et al: Disseminated infection due to Scedosporium apiospermum in a patient with acute myelogenous leukemia. Leuk Lymphoma 2003; 44:369-372
60. Pizzo PA, Robichaud KJ, Gill FA, et al: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-111
61. Empiric antifungal therapy in febrile granulocytopenic patients: EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989; 86(6 Pt 1):668-672
62. Walsh TJ, Finberg RW, Arndt C, et al: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia: National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764-771
63. Boogaerts M, Winston DJ, Bow EJ, et al: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: A randomized, controlled trial. Ann Intern Med 2001; 135:412-422
64. Walsh TJ, Pappas P, Winston DJ, et al: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-234
65. Herbrecht R, Denning DW, Patterson TF, et al: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415
66. Kirkpatrick WR, Perea S, Coco BJ, et al: Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46:2564-2568
67. Petraitis V, Petraitiene R, Sarafandi AA, et al: Combination therapy in treatment of experimental pulmonary aspergillosis: Synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187:1834-1843
68. Rex JH, Bennett JE, Sugar AM, et al: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia: Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325-1330
69. Phillips P, Shafran S, Garber G, et al: Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients: Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16:337-345
70. Mora-Duarte J, Betts R, Rotstein C, et al: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-2029
71. Rex JH, Pappas PG, Karchmer AW, et al: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36:1221-1228
72. Rex JH, Walsh TJ, Sobel JD, et al: Practice guidelines for the treatment of candidiasis: Infectious Diseases Society of America. Clin Infect Dis 2000; 30:662-678
73. Arikan S, Lozano-Chiu M, Paetznick V, et al: In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001; 45:327-330
74. Laverdiere M, Hoban D, Restieri C, et al: In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 2002; 50:119-123
75. Pfaller MA, Diekema DJ, Messer SA, et al: In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003; 47:1068-1071
76. Stone EA, Fung HB, Kirschenbaum HL: Caspofungin: an echinocandin antifungal agent. Clin Ther 2002; 24:351-377
77. Pfaller MA, Messer SA, Mollis RJ, et al: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46:1032-1037
78. Sutton DA: Laboratory evaluation of new antifungal agents against rare and refractory mycoses. Curr Opin Infect Dis 2002; 15:575-582
79. Bowden R, Chandrasekar P, White MH, et al: A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-366
80. Cagnoni PJ, Walsh TJ, Prendergast MM, et al: Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000; 18:2476-2483
81. Ullmann AJ: Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 2003; 19:263-271
82. Romero AJ, Pogamp PL, Nilsson LG, et al: Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002; 71:226-234
83. Venkataramanan R, Zang S, Gayowski T, et al: Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002; 46: 3091-3093
84. Pai MP, Allen S: Voriconazole inhibition of tacrolimus metabolism. Clin Infect Dis 2003; 36:1089-1091
85. Scherpbier HJ, Hilhorst MI, Kuijpers TW: Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. Clin Infect Dis 2003; 37:828-830
86. Price NO, Hacker JK, Silvers JH, et al: Adenovirus type 3 viremia in an adult with toxic shock-like syndrome. Clin Infect Dis 2001; 33:260-262
87. Zahariadis G, Jerome KR, Corey L: Herpes simplex virus-associated sepsis in a previously infected immunocompetent adult. Ann Intern Med 2003; 139:153-154
88. Shorr AF, Abbott KC, Agadoa LY: Acute respiratory distress syndrome after kidney transplantation: Epidemiology, risk factors, and outcomes. Crit Care Med 2003; 31: 1325-1330
89. Baughman RP: Cytomegalovirus: The monster in the closet? Am J Respir Crit Care Med 1997; 156:1-2
90. Ljungman P: Definitions of cytomegalovirus infection and disease in transplant patients. Clin Infect Dis 2002; 34:1094-1097
91. Nichols WG, Corey L, Gooley T, et al: Para-influenza virus infections after hematopoietic stem cell transplantation: Risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98: 573-578
92. Ghosh S, Champlin RE, Ueno NT, et al: Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: Combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant 2001; 28:271-275
93. Small TN, Casson A, Malak SF, et al: Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29:321-327
94. Chakrabarti S, Avivi I, Mackinnon S, et al: Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: High incidence but low mortality. Br J Haematol 2002; 119:1125-1132
95. Ljungman P, Ward KN, Crooks BN, et al: Respiratory virus infections after stem cell transplantation: A prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28:479-484
96. McCarthy AJ, Kingman HM, Kelly C, et al: The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant 1999; 24:1315-1322
97. Abdallah A, Rowland KE, Schepetiuk SK, et al: An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: Effect on engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant 2003; 32: 195-203
98. Ljungman P, Ribaud P, Eyrich M, et al: Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: A survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31:481-486
99. Morishita K, Kodo H, Asano S, et al: Fulminant varicella hepatitis following bone marrow transplantation. JAMA 1985; 253:511
100. Johnson JR, Egaas S, Cleaves CA, et al: Hepatitis due to herpes simplex virus in marrow-transplant recipients. Clin Infect Dis 1992; 14:38-45
101. Wang WH, Wang HL: Fulminant adenovirus hepatitis following bone marrow transplantation: A case report and brief review of the literature. Arch Pathol Lab Med 2003; 127: e246-e248
102. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18:3558-3585
103. Garcia-Carbonero R, Mayordomo JI, Tomamira MV, et al: Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial. J Natl Cancer Inst 2001; 93:31-38
104. Ahmad A, Laborada G, Bussel J, et al: Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants. Pediatr Infect Dis J 2002; 21:1061-1065
105. Bernstein HM, Pollock BH, Calhoun DA, et al: Administration of recombinant granulocyte colony-stimulating factor to neonates with septicemia: A meta-analysis. J Pediatr 2001; 138:917-920
106. Bilgin K, Yaramis A, Haspolat K, et al: A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 2001; 107:36-41
107. Bedford Russell AR, Emmerson AJ, Wilkinson N, et al: A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia. Arch Dis Child Fetal Neonatal Ed 2001; 84:F172-F176
108. Presneill JJ, Harris T, Stewart AG, et al: A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002; 166:138-143
109. Root RK, Lodato RF, Patrick W, et al: Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31:367-373
110. Niederman MS: Granulocyte colony-stimulating factor for severe pneumonia: What do we do when the best laid plans for men (and mice and rats) fail? Crit Care Med 2003; 31:635-637
111. Cheng A, Stephens D, Currie B: Granulocyte colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 2003; 4:CD004400
112. Cheng AC, Stephens DP, Anstey NM, et al: Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 2004; 38:32-37
113. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
114. Pastores SM, Papadopoulos E, van den Brink M, et al: Septic shock and multiple organ failure after hematopoietic stem cell transplantation: Treatment with recombinant human activated protein C. Bone Marrow Transplant 2002; 30:131-134
115. Bollaert PE, Charpentier C, Levy B, et al: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645-650
116. Briegel J, Forst H, Haller M, et al: Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27:723-732
117. Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
118. Goodman S, Sprung CL: The International Sepsis Forum's controversies in sepsis: Corticosteroids should be used to treat septic shock. Crit Care 2002; 6:381-383
119. Bernard G: The International Sepsis Forum's controversies in sepsis: Corticosteroids should not be routinely used to treat septic shock. Crit Care 2002; 6:384-386
120. Balk RA: Steroids for septic shock: Back from the dead? (Pro). Chest 2003; 123(5 Suppl):490S-499S.
121. Sessler CN: Steroids for septic shock: back from the dead? (Con). Chest 2003; 123(5 Suppl):482S-489S
122. Abraham E, Evans T: Corticosteroids and septic shock. JAMA 2002; 288:886-887
123. Opal SM: Corticosteroids for patients with septic shock. JAMA 2003; 289:41-42; author reply, 43-44
124. Yildiz O, Doganay M, Aygen B, et al: Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 2002; 6:251-259
125. Soni A, Pepper GM, Wyrwinski PM, et al: Adrenal insufficiency occurring during septic shock: Incidence, outcome, and relationship to peripheral cytokine levels. Am J Med 1995; 98:266-271
126. Matot I, Sprung CL: Corticosteroids in septic shock: Resurrection of the last rites? Crit Care Med 1998; 26:627-630
127. Bornstein SR, Briegel J: A new role for glucocorticoids in septic shock: Balancing the immune response. Am J Respir Crit Care Med 2003; 167:485-486
128. Keh D, Boehnke T, Weber-Cartens S, et al: Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: A double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003; 167:512-520
129. Hecht FM, Wilson IB, Wu AW, et al: Optimizing care for persons with HIV infection. Ann Intern Med 1999; 131:136-143
130. Du B, Long Y, Liu H, et al: Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: Risk factors and clinical outcome. Intensive Care Med 2002; 28:1718-1723
131. Anderson KB, Tan JS, File TM Jr, et al: Emergence of levofloxacin- resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003; 37:376-381
132. Romero AJ, Pogamp PL, Nilsson LG, et al: Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002; 71:226-234
133. Wingard JR, Kubilis P, Lee L, et al: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29:1402-1407
134. Ng HJ, Lim LC: Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: Case report. Ann Hematol 2001; 80:549-552
135. Lortholary O, Mainardi JL, La Scola B, et al: Consecutive bacillary angiomatosis and Rhodococcus equi bacteremia during acute leukemia: Zoonoses may cause fever in neutropenic patients. Clin Microbiol Infect 2000; 6:334-336
136. Mahaffey KW, Hippenmeyer CL, Mandel R, et al: Unrecognized coccidioidomycosis complicating Pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus and treated with corticosteroids: A report of two cases. Arch Intern Med 1993; 153:1496-1498
137. Husni RN, Gordon SM, Longworth DL, et al: Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26:753-755
138. Nichols WG, Corey L, Gooley T, et al: High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185:273-282
139. Fukuda T, Boeckh M, Carter RA, et al: Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827-833
140. Sparrelid E, Hagglund H, Remberger M, et al: Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998; 22:795-800
141. Williamson EC, Millar MR, Steward CG, et al: Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999; 104:560-568
142. Nichols WG, Corey L, Gooley T, et al: Parainfluenza virus infections after hematopoietic stem cell transplantation: Risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98: 573-578
143. Lieberman D, Porath A, Schlaeffer F, et al: Legionella species community-acquired pneumonia: A review of 56 hospitalized adult patients. Chest 1996; 109:1243-1249
144. Clark TM, Burman WJ, Cohn DL, et al: Septic shock from Mycobacterium tuberculosis after therapy for Pneumocystis carinii. Arch Intern Med 1998; 158: 1033-1035
145. Holland SM: Host defense against nontuberculous mycobacterial infections. Semin Respir Infect 1996; 11:217-230
146. Segal BH, Leto TL, Gallin JI, et al: Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000; 79:170-200